WO2001027245A3 - Generation and characterization of a dendritic cell isolated from human peripheral blood mononuclear cells - Google Patents

Generation and characterization of a dendritic cell isolated from human peripheral blood mononuclear cells Download PDF

Info

Publication number
WO2001027245A3
WO2001027245A3 PCT/US2000/027651 US0027651W WO0127245A3 WO 2001027245 A3 WO2001027245 A3 WO 2001027245A3 US 0027651 W US0027651 W US 0027651W WO 0127245 A3 WO0127245 A3 WO 0127245A3
Authority
WO
WIPO (PCT)
Prior art keywords
peripheral blood
dendritic cell
blood mononuclear
mononuclear cells
human peripheral
Prior art date
Application number
PCT/US2000/027651
Other languages
French (fr)
Other versions
WO2001027245A2 (en
Inventor
Tatsue Monji
Madhusudan V Peshwa
Original Assignee
Dendreon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dendreon Corp filed Critical Dendreon Corp
Priority to AU78674/00A priority Critical patent/AU7867400A/en
Priority to CA002385792A priority patent/CA2385792A1/en
Priority to JP2001530450A priority patent/JP2003511064A/en
Priority to EP00968813A priority patent/EP1224262A2/en
Publication of WO2001027245A2 publication Critical patent/WO2001027245A2/en
Publication of WO2001027245A3 publication Critical patent/WO2001027245A3/en
Priority to HK02106764.9A priority patent/HK1045329A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components

Abstract

A dendritic cell (DC) composition and a method of obtaining such a composition by isolating and culturing human peripheral blood mononuclear cells (PBMC) is described, together with methods of identifying and isolating DC at two different stages of maturation [the DC precursor (DCP) stage and the mature DC stage]. Also described are methods of activating T-cells employing such a DC composition.
PCT/US2000/027651 1999-10-08 2000-10-06 Generation and characterization of a dendritic cell isolated from human peripheral blood mononuclear cells WO2001027245A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU78674/00A AU7867400A (en) 1999-10-08 2000-10-06 Generation and characterization of a dendritic cell isolated from human peripheral blood mononuclear cells
CA002385792A CA2385792A1 (en) 1999-10-08 2000-10-06 Generation and characterization of a dendritic cell isolated from human peripheral blood mononuclear cells
JP2001530450A JP2003511064A (en) 1999-10-08 2000-10-06 Production and characterization of dendritic cells from human peripheral blood mononuclear cells
EP00968813A EP1224262A2 (en) 1999-10-08 2000-10-06 Generation and characterization of a dendritic cell isolated from human peripheral blood mononuclear cells
HK02106764.9A HK1045329A1 (en) 1999-10-08 2002-09-14 Generation and characterization of a dendritic cell isolated from human peripheral blood mononuclear cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15861899P 1999-10-08 1999-10-08
US60/158,618 1999-10-08

Publications (2)

Publication Number Publication Date
WO2001027245A2 WO2001027245A2 (en) 2001-04-19
WO2001027245A3 true WO2001027245A3 (en) 2001-12-13

Family

ID=22568957

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/027651 WO2001027245A2 (en) 1999-10-08 2000-10-06 Generation and characterization of a dendritic cell isolated from human peripheral blood mononuclear cells

Country Status (6)

Country Link
EP (1) EP1224262A2 (en)
JP (1) JP2003511064A (en)
AU (1) AU7867400A (en)
CA (1) CA2385792A1 (en)
HK (1) HK1045329A1 (en)
WO (1) WO2001027245A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7097833B2 (en) 2002-07-19 2006-08-29 Boston Scientific Scimed, Inc. Selected cell delivery for heart failure
AU2002950778A0 (en) * 2002-08-15 2002-09-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland A method of characterizing dendritic cells
AU2003254382B2 (en) * 2002-08-15 2008-11-13 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland A method of characterizing dendritic cells
JP2007537975A (en) * 2003-06-10 2007-12-27 ザ　ユニバーシティー　オブ　メルボルン Immunomodulatory compositions, methods for their use and methods for their manufacture
ATE544849T1 (en) 2004-07-08 2012-02-15 Medinet Co Ltd ACTIVATED DENDRITIC CELLS, THERAPY METHOD USING THE DENDRITIC CELLS AND METHOD FOR CULTIVATION OF GAMMA DELTA T CELLS
CA2682661C (en) * 2007-03-22 2017-03-14 Dendreon Corporation Methods for inducing a natural killer (nk) cell-mediated immune response and for increasing nk cell activity
KR101349249B1 (en) * 2007-08-24 2014-01-10 (주)아모레퍼시픽 In vitro skin sensitization test method
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
EP2505640A1 (en) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Vaccine compositions for birnavirus-borne diseases
JP6712262B2 (en) * 2014-09-10 2020-06-17 ミルテニー バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｉｌｔｅｎｙｉ Ｂｉｏｔｅｃ ＧｍｂＨ Cell populations for use in immunotherapy
WO2016145317A1 (en) * 2015-03-12 2016-09-15 Thomas Schwaab Enrichment of cd16+ monocytes to improve dendritic cell vaccine quality
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
CN109679903A (en) * 2019-01-16 2019-04-26 深圳咖荻生物科技有限公司 Separation and purification method of T lymphocytes
CN113151169A (en) * 2021-05-14 2021-07-23 上海赛笠生物科技有限公司 Method for separating natural killer cells based on magnetic bead positive selection strategy
CN116103234B (en) * 2023-04-13 2023-06-23 天津纽赛生物技术有限公司 Preparation method and application of novel DC-like cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029182A1 (en) * 1996-02-12 1997-08-14 The Rockefeller University Method and compositions for obtaining mature dendritic cells
WO1998006823A2 (en) * 1996-08-14 1998-02-19 Nexell Therapeutics Inc. Cytokine-free culture of dendritic cells
WO1999025812A1 (en) * 1997-11-14 1999-05-27 Hemosol Inc. Method for the production and use of dendritic cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029182A1 (en) * 1996-02-12 1997-08-14 The Rockefeller University Method and compositions for obtaining mature dendritic cells
WO1998006823A2 (en) * 1996-08-14 1998-02-19 Nexell Therapeutics Inc. Cytokine-free culture of dendritic cells
WO1999025812A1 (en) * 1997-11-14 1999-05-27 Hemosol Inc. Method for the production and use of dendritic cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RAJE NOOPUR ET AL: "Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences.", BLOOD, vol. 93, no. 5, 1 March 1999 (1999-03-01), pages 1487 - 1495, XP002165726, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
EP1224262A2 (en) 2002-07-24
AU7867400A (en) 2001-04-23
CA2385792A1 (en) 2001-04-19
HK1045329A1 (en) 2002-11-22
JP2003511064A (en) 2003-03-25
WO2001027245A2 (en) 2001-04-19

Similar Documents

Publication Publication Date Title
WO2001027245A3 (en) Generation and characterization of a dendritic cell isolated from human peripheral blood mononuclear cells
EP2722387A3 (en) Definitive endoderm
AU2003209259A1 (en) Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
WO2000003000A3 (en) Serum-free medium for culturing animal cells
AU2002361468A1 (en) Method for rapid generation of mature dendritic cells
AU1796601A (en) Methods of preparing electrochemical cells
EP2650360A3 (en) Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
WO2003081201A3 (en) Peripheral blood cell markers useful for diagnosing multiple sclerosis and methods and kits utilizing same
EP1449916A3 (en) Submucosa as a growth substrate for cells
AU6874798A (en) Microelectronic biosensor and method of monitoring cultured cells
CA2189646A1 (en) A Purified Mixture of Collagenases and Two Other Proteases Obtained from Clostridium Histolyticum
WO2003024406A3 (en) Nestin-expressing hair follicle stem cells
WO2002083864A3 (en) Methods and reagents for cell transplantation
CA2415749A1 (en) Method of producing infectious reovirus
AU2003238801A1 (en) Electrochemical cell and bipolar assembly for an electrochemical cell
AU2003261308A1 (en) Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays
HK1048498A1 (en) Method of proliferating natural killer cells
WO2003089581A3 (en) A method to increase the rate of cell growth
EP2377922A3 (en) PDX1 expressing endoderm
AU1796501A (en) Methods of preparing electrochemical cells
AU3434801A (en) Fuel cell bipolar separator plate and current collector assembly and method of manufacture
AU2002350139A1 (en) Production of cell suspensions
AU2003287521A1 (en) Pluripotent cells from monocytes, and methods of making and using pluripotent cells
WO2004013288A3 (en) Methods and kits for synthesis of sirna expression cassettes
WO2001049821A3 (en) Th1 specific cd4 t cell lines and method for inducing them ex vivo

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP NZ

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP NZ

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 2385792

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 530450

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 78674/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 518732

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2000968813

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000968813

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000968813

Country of ref document: EP